A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer
A phase 2 trial of Abiraterone acetate, Prednisone in prostate cancer, run by R-Pharm International, LLC, active and no longer recruiting.
Overview
A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer is a phase 2 interventional study registered as NCT07553988 by R-Pharm International, LLC, with 120 participants planned, started 2024-10-24 and due to reach its primary completion in 2026-05-14. Interventions recorded: RS-113, 160 mg, RS-113, 240 mg, RS-113, 320 mg, Abiraterone, Prednisolone. Conditions listed: Metastatic Castration-resistant Prostate Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Ver
Shares Prednisone, Abiraterone acetate, Prostate cancer.
- TrialA Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
Shares Prednisone, Abiraterone acetate, Prostate cancer.
- TrialA Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Shares Prednisone, Abiraterone acetate, Prostate cancer.
- TrialA Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
Shares Prednisone, Abiraterone acetate, Prostate cancer.
- TrialA Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
Shares Prednisone, Abiraterone acetate, Prostate cancer.
- TrialAn Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Shares Prednisone, Abiraterone acetate, Prostate cancer.
- TrialA Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Shares Prednisone, Abiraterone acetate, Prostate cancer.
- TrialA Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Shares Prednisone, Abiraterone acetate, Prostate cancer.